Novel bioabsorbable salicylate‐based polymer as a drug‐eluting stent coating

Jabara, Refat; Chronos, Nicolas; Robinson, Keith A.

doi:10.1002/ccd.21607

Cited by 62 publications

(36 citation statements)

References 32 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most notably, the polymer was associated with reduced inflammation compared with a standard BMS and Cypher stent. 81 This was very likely due to the antiinflammatory properties of salicylic acid following absorption by the vessel wall after its release. Drug elution was found to be complete after 30 days, and complete stent degradation occurred over a 9-to 12-month period.…”

Section: Poly (Anhydride Ester) Salicylic Acid: the Ideal Stentmentioning

confidence: 99%

Bioresorbable Scaffold

Onuma¹,

Serruys²

2011

Circulation

393

151

View full text Add to dashboard Cite

T he invention of balloon angioplasty as a percutaneous treatment for obstructive coronary disease by Andreas Gruntzig in 1977 was a huge leap forward in cardiovascular medicine and undoubtedly will always be remembered as a revolution in the field of revascularization. However, this technique was plagued by multiple problems, including the risk of acute vessel closure secondary to occlusive coronary dissection, sometimes necessitating emergency coronary artery bypass surgery. 1-3 Although late luminal enlargement and vascular remodeling could take place, more often restenosis 4 -8 would occur instead. The restenosis would essentially be caused by constrictive remodeling 9 -13 and, to a lesser extent, by elastic recoil 14 or the neointimal hyperplastic healing response. [15][16][17] The advent of bare metal stenting (BMS) and the landmark Belgian-Netherlands Stent Study (BENESTENT) and Stent Restenosis Study (STRESS) trials have established BMS as the second revolution in interventional cardiology. 18,19 This technology provided a solution to acute vessel occlusion by sealing the dissection flaps and preventing recoil. The rate of subacute occlusion was reduced to 1.5%, making emergency bypass surgery a rare occurrence. Restenosis rates were further reduced from 32% to 22% at 7 months, but this rate was still high, and neointimal hyperplasia inside the stent was even more prominent than with angioplasty, necessitating repeat treatment in numerous patients. 18 Because the vessel was now caged with metal, late luminal enlargement and advantageous vascular remodeling could no longer occur. Another problem, namely late stent thrombosis (ST), was also first described. 20 To solve the problem of in-stent restenosis, after the historic failure of brachytherapy to resolve this problem, 21,22 drug-eluting stents (DES) were introduced. The first 45 patients implanted with the sirolimuseluting Bx velocity stent (Cordis, Johnson & Johnson, Warren, NJ) were found to have negligible neointimal hyperplasia at follow-up. 23,24 This was confirmed in the randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization (RAVEL) study. 25,26 The introduction of DES was thus dubbed the third revolution in interventional cardiology. Both large-scale randomized trials and all-comer registries showed excellent results in terms of the need for repeat revascularization. However, the early enthusiasm has been tempered in recent years after widespread concerns about the increased risk of late and very late ST. [27][28][29][30][31] Registries of all comers treated with DES showed late ST rates of 0.53%/y, with a continued increase to 3% over 4 years. 32,33 In the Arterial Revascularization Therapies Study II (ARTS II) trial, which enrolled patients with complex multivessel disease, the rate of combined definite, probable, and possible ST was as high as 9.4% at 5 years, accounting for 32% of major adverse cardiovascular events (MACEs). 34 In addition, postmortem pathological specimens of DES revealed sig...

show abstract

Section: Poly (Anhydride Ester) Salicylic Acid: the Ideal Stentmentioning

confidence: 99%

Bioresorbable Scaffold

Onuma¹,

Serruys²

2011

Circulation

393

151

View full text Add to dashboard Cite

show abstract

“…Preclinical studies have demonstrated the potential benefit of the anti-inflammatory properties of salicylic acid in combination with an antiproliferative drug. In vitro studies demonstrated a complete stent degradation over 12 months [58,59]. The safety and efficacy of the IDEAL BRS was evaluated in the WHISPER FIM (n = 11).…”

Section: Ideal Bioresorbable Scaffoldmentioning

confidence: 99%

Bioresorbable scaffolds for the treatment of coronary artery disease: current status and future perspective

Kraak

Grundeken

Koch

et al. 2014

Expert Review of Medical Devices

View full text Add to dashboard Cite

Bioresorbable scaffolds represent a novel approach in the treatment of coronary artery disease which allows for vessel wall support without leaving a permanent foreign body in the coronary artery. This technology has the potential to reduce some of the shortcomings of current standard treatment with metallic drug-eluting stents, such as late in-stent restenosis, impaired vasomotion of the stented segment and hindrance of surgical revascularizations. Currently, several bioresorbable scaffolds are available and undergoing clinical or preclinical evaluation. This review will present the current status of development of bioresorbable scaffolds, describe the degradation/resorption process of each device and the clinical data available to date.

show abstract

“…Preclinical data are awaited for this iteration. 49 Future of BVS DES is a major breakthrough in interventional cardiology because they reduced the need for repeat intervention compared with BMS by more than 50%. Late (6 month to 1 year) or very late (beyond 1 year) thrombosis is the feared complication of DES that may result in myocardial infarction and death.…”

Section: Biodegradable Magnesium Stentmentioning

confidence: 99%

Bioabsorbable Vascular Scaffold: A Revolution in Coronary Intervention

2014

View full text Add to dashboard Cite

Since the advent of percutaneous coronary angioplasty in 1977, immense experiment has been done to improve the outcome of the patients with coronary artery disease. Lot of trials have been done with angioplasty, bare metal stents, drug eluting stents, drug eluting balloons and other devices. Bioabsorbable vascular stents are relatively newcomers in this field with a lot of hope. We tried to update the latest status of Bioabsorbable vascular stents in this review, specially the short and midterm safety and efficacy and some of their limitations. DOI: http://dx.doi.org/10.3329/cardio.v6i2.18359 Cardiovasc. j. 2014; 6(2): 149-163

show abstract

Novel bioabsorbable salicylate‐based polymer as a drug‐eluting stent coating

Abstract: This study shows favorable vascular compatibility and efficacy for a novel bioabsorbable salicylate-based polymer as a DES coating, and supports further research and development of this unique class of polymer materials for applications in cardiovascular devices.

Cited by 62 publications

References 32 publications

Bioresorbable Scaffold

Bioresorbable Scaffold

Bioresorbable scaffolds for the treatment of coronary artery disease: current status and future perspective

Bioabsorbable Vascular Scaffold: A Revolution in Coronary Intervention

Contact Info

Product

Resources

About